R 801

Drug Profile

R 801

Alternative Names: R-801

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Radikal Therapeutics
  • Developer Radikal Therapeutics; Tisbury Pharmaceuticals
  • Class Eye disorder therapies; Small molecules; Urologics
  • Mechanism of Action KATP channel stimulants; Superoxide dismutase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Kidney disorders; Open-angle glaucoma; Reperfusion injury
  • No development reported Bronchopulmonary dysplasia

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Bronchopulmonary-dysplasia(In neonates) in USA (Parenteral)
  • 04 Jan 2018 Preclinical trials in Open angle glaucoma in USA before January 2018 (Tisbury Pharmaceuticals pipeline, January 2018)
  • 04 Jan 2018 Preclinical data in open angle glaucoma released by Tisbury Pharmaceuticals (Tisbury Pharmaceuticals pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top